Items | Number of patients (of 96) consistent with the standards in cycle A | Number of patients (of 111) consistent with the standards in cycle B |
---|---|---|
Indication | 81 (84.38%) | 105 (94.59%) |
Drug monitoring | Ā | Ā |
āLife index record | 96 (100%) | 111 (100%) |
āBlood examination | 85 (88.54%) | 108 (97.30%) |
āLiver function monitoring | 75 (78.12%) | 101 (90.99%) |
āRenal function monitoring | 72 (75.00%) | 107 (96.40%) |
āBacterial culture and sensitivity test | 60 (65.22%)* | 98 (88.29%) |
āDrug skin test | 96 (100%) | 111 (100%) |
Dosage | Ā | Ā |
āDose and duration | 70 (72.92%) | 100 (90.09%) |
āDosing frequency | 70 (72.92%) | 100 (90.09%) |
āSolvent selection | 96 (100.00%) | 110 (99.10%) |
āRoute of administration | 96(100.00%) | 111 (100.00%) |
āCompatibility | 95 (98.96%) | 111 (100.00%) |
Replacement drugs | 84 (87.50%) | 104 (93.69%) |
Combined medication (drug-drug interaction) | 58 (62.37%)* | 89 (80.18%) |
Adverse drug reactions | 8 (8.33%) | 7 (6.31%) |
Outcome | 83 (91.21%) | 102 (95.33%) |